## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-muscle-loss`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-muscle-loss/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-muscle-loss` v2 · content_hash `ae662a05c724f37d…` · thread_head genesis · 18 DIVs
- **thesis (c1):** SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.
  - c2 [human/active] A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.
  - c3 [human/active] Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.
  - c4 [preclinical/active] In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.
  - c5 [preclinical/active] SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.
  - c6 [anecdotal/active] Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-muscle-loss/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-muscle-loss/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-muscle-loss`
- **title:** SS-31 (Elamipretide) for Muscle Loss: Mitochondrial Evidence Breakdown
- **url:** https://miscsubjects.com/a/ss-31-muscle-loss
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:05.916Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Muscle loss with age, often called sarcopenia, involves multiple layers. One key layer is mitochondrial decline inside muscle cells. Mitochondria produce ATP for contraction and repair. With age, they generate more reactive oxygen species, lose efficiency in oxidative phosphorylation, and show reduced ADP sensitivity. This leads to lower energy output, oxidative damage to proteins, and impaired muscle performance and maintenance. If mitochondrial dysfunction outpaces repair mechanisms, muscle mass and strength decline over time.

## Why SS-31 (Elamipretide) might help you

1. If mitochondrial oxidative stress and poor ATP production contribute to your muscle loss, SS-31 binds cardiolipin in the inner mitochondrial membrane. 2. This stabilizes the membrane, improves electron transport chain efficiency, and lowers excess ROS production. 3. Therefore for you: If that layer is part of your problem, SS-31 is discussed because it targets repair (tissue) — not because it masks pain. 4. Better mitochondrial function can support muscle fiber maintenance and fatigue resistance instead of allowing further breakdown.

## How these fit together

Single-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer of degeneration. If your profile includes other layers like inflammation or hormonal decline, additional approaches would address those separately.

## What the evidence actually shows

Preclinical studies in aged mice show SS-31 improves skeletal muscle mitochondrial ATP production, reverses age-related redox stress, increases fatigue resistance, and boosts exercise tolerance (Campbell et al. 2019; Siegel et al. 2013). One 2026 rat model of HFpEF found it improved soleus and EDL muscle contractile function and prevented atrophy development. A 2022 mouse study after spinal cord injury found no prevention of muscle atrophy at 7 days. Human data: A randomized trial showed a single dose improved in vivo mitochondrial ATP production in older adult skeletal muscle. Phase 2 trials in primary mitochondrial myopathy showed some exercise gains; phase 3 did not meet primary endpoints on walking distance. In Barth syndrome (mitochondrial cardiolipin disorder with muscle weakness), long-term data supported accelerated approval for muscle strength improvement.

## What scientists say

Researchers note SS-31 rapidly improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator and stabilizes cardiolipin. They highlight benefits for mitochondrial myopathies and age-related muscle function but emphasize mixed human trial results outside specific genetic conditions. Preclinical consistency on energetics contrasts with translation challenges in broader sarcopenia.

## What people say on Reddit

Anecdotal reports in ME/CFS communities mention perceived muscle strength gains in isolated cases, with one user noting dramatic improvement allowing weight lifting. Others report no noticeable effect or discuss cost barriers from trial doses around 40 mg daily. Discussions often reference mitochondrial myopathy trials and stress pacing alongside any use.

## What people say on X

Limited public posts discuss SS-31 primarily in context of mitochondrial disorders or research updates; few direct anecdotes on general muscle loss appear in recent searches.

## What we do not know

No large human trials specifically target age-related sarcopenia or general muscle loss. Long-term effects on muscle mass versus function remain unclear outside rare diseases. Optimal duration, combination strategies, and identification of responders based on mitochondrial status need more data.

## Safety and limits

Clinical trials report generally good tolerability with subcutaneous or IV administration. Some phase 3 programs showed no major safety signals but lacked efficacy on primary measures. Individual responses vary; it is not approved for general muscle loss. Evidence is strongest in mitochondrial-specific conditions.

## Claims (6)

- **c1** [preclinical w=0.5] SS-31 improves mitochondrial ATP production and exercise tolerance in aged mice.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] A single dose of elamipretide improved in vivo mitochondrial ATP production in older adult skeletal muscle in a randomized trial.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [human w=0.8] Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy did not meet primary endpoints on walking distance or fatigue.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [preclinical w=0.5] In a 2026 HFpEF rat model, elamipretide improved muscle contractile function and prevented atrophy.
  - who_claims: grok/grok-4.3
  - sources: s4
- **c5** [preclinical w=0.5] SS-31 did not prevent muscle atrophy 7 days post-SCI in young male mice.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c6** [anecdotal w=0.3] Anecdotal reports on Reddit include perceived muscle strength gains in some ME/CFS users.
  - who_claims: grok/grok-4.3
  - sources: s6

## Voxel graph (6 atoms · 12 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-muscle-loss/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (6)
- chain valid: yes · head: `caa23887c3917662`

### s1 · pubmed · ok
- title: Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/
- summary: Aged mice study showing mitochondrial and functional muscle benefits.
- quote: Treatment with SS-31 restores redox homeostasis, improves mitochondrial quality, and increases exercise tolerance without an increase in mitochondrial content.
- claim_ids: c1
- hash: `8dee10a450c5984e`

### s2 · pubmed · ok
- title: In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
- url: https://pubmed.ncbi.nlm.nih.gov/34242343/
- summary: Human randomized trial on ATP in aging muscle.
- quote: In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial.
- claim_ids: c2
- hash: `930ef738b977a9c9`

### s3 · pubmed · ok
- title: Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
- url: https://www.neurology.org/doi/10.1212/WNL.0000000000005255
- summary: Phase 1/2 and later phase 3 context for PMM.
- quote: Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.
- claim_ids: c3
- hash: `fefa0b9d9798a0af`

### s4 · pubmed · http_403
- title: Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model
- url: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.126.014397
- summary: 2026 rat study on muscle performance and atrophy prevention.
- quote: Elamipretide improved whole muscle contractile function and prevented atrophy development.
- claim_ids: c4
- hash: `607f72b27e049f45`

### s5 · pubmed · ok
- title: SS‐31 does not prevent or reduce muscle atrophy 7 days after a 65 kdyne contusion spinal cord injury in young male mice
- url: https://physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.15266
- summary: Negative finding in SCI atrophy model.
- quote: SS-31 did not preserve body mass or hindlimb muscle mass 7 days post-SCI.
- claim_ids: c5
- hash: `24a9b4f86698e2ee`

### s6 · reddit · ok
- title: My Experience Treating my ME/CFS with mitochondrial peptides
- url: https://www.reddit.com/r/cfs/comments/1j2upcm/my_experience_treating_my_mecfs_with/
- summary: User reports of muscle strength changes with SS-31.
- quote: i notice very dramatic improvement to muscle strength on the ...
- claim_ids: c6
- hash: `caa23887c3917662`

## Provenance (2 model passes)
- chain valid: yes · head: `50172c91001aedb9`

- write · grok/grok-4.3 · 2026-06-29T23:51 · hash `1369e0bd23f4`
- voxel_divide · owner · 2026-07-17T02:42 · hash `50172c91001a`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-muscle-loss/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-muscle-loss/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-muscle-loss","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-muscle-loss|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-muscle-loss|tier|assertion`
- **iMessage ask:** `ss-31-muscle-loss|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-muscle-loss`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-muscle-loss/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*